Cheshire William P, Abashian Sandra W, Mann Douglas J
Department of Neurology, University of North Carolina, 751 Clinical Sciences Building, Chapel Hill, NC 27599 USA.
Pain. 1994 Oct;59(1):65-69. doi: 10.1016/0304-3959(94)90048-5.
Six patients with chronic myofascial pain syndrome involving cervical paraspinal and shoulder girdle muscles received trigger point injections of botulinum toxin type A (Botox) or saline in a randomized, double-blind, placebo-controlled study. Four patients experienced reduction in pain of at least 30% following Botox, but not saline, injections, as measured by visual analog scales, verbal descriptors for pain intensity and unpleasantness, palpable muscle firmness, and pressure pain thresholds. Results were statistically significant. Botox, which inhibits muscle contraction by blocking the release of acetylcholine from peripheral nerves, appears to be an effective treatment for focal myofascial pain disorders.
在一项随机、双盲、安慰剂对照研究中，六名患有涉及颈旁脊柱和肩带肌的慢性肌筋膜疼痛综合征的患者接受了A型肉毒杆菌毒素（保妥适）或生理盐水的触发点注射。通过视觉模拟量表、疼痛强度和不适感的语言描述、可触及的肌肉硬度以及压痛阈值测量发现，四名患者在接受保妥适注射而非生理盐水注射后疼痛减轻了至少30%。结果具有统计学意义。保妥适通过阻断外周神经释放乙酰胆碱来抑制肌肉收缩，似乎是治疗局部肌筋膜疼痛障碍的有效方法。
